HSV529

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Fred Hutchinson Cancer Center

Conditions

Healthy VolunteersHerpes Simplex Virus 2

Phase 1

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

CompletedNCT01915212

National Institute of Allergy and Infectious Diseases (NIAID)Healthy Volunteers

Start: 2013-09-26End: 2017-03-06Updated: 2026-09-01

HSV529 Vaccine in HSV-2 Seropositive Adults

CompletedNCT02571166

Fred Hutchinson Cancer CenterHerpes Simplex Virus 2

Start: 2015-11-30End: 2018-12-01Updated: 2019-01-14

Related Papers

Sex and prior exposure jointly shape innate immune responses to a live herpesvirus vaccine

eLife2022-12-168 citations

A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection

The Journal of Infectious Diseases2019-05-0363 citations

A Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals

Open Forum Infectious Diseases2017-01-0111 citations